APTAMER GROUP PLC Logo

APTAMER GROUP PLC

Develops custom aptamer-based binders as antibody alternatives for life science applications.

APTA | IL

Overview

Corporate Details

ISIN(s):
GB00BNRRP542
LEI:
213800Y4XGH3WJNBE686
Country:
United Kingdom
Address:
WINDMILL HOUSE, YO10 5BR YORK
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Aptamer Group PLC is a leading developer of custom affinity binders for the life sciences industry through its proprietary Optimer® platform. Optimer binders are next-generation, aptamer-based synthetic ligands engineered to provide high affinity, specificity, and stability. The company offers custom discovery and development services, delivering innovative solutions that serve as alternatives to traditional binders like antibodies. These solutions are utilized across a wide range of applications, including therapeutics, diagnostics, research, and bioprocessing, supporting a global client base of biotechnology and pharmaceutical companies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for APTAMER GROUP PLC and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 08:00
Regulatory News Service
New contract with Metir plc
English 17.0 KB
2025-09-09 08:00
Director's Dealing
Notification of dealings by a director/PDMR
English 23.8 KB
2025-09-02 08:00
Regulatory News Service
Therapeutic development agreement with Invizius
English 18.4 KB
2025-08-28 08:00
Share Issue/Capital Change
Block Listing Interim Review
English 14.9 KB
2025-08-22 08:00
Regulatory News Service
Update on licensing and development progress
English 19.5 KB
2025-08-19 08:00
Share Issue/Capital Change
Exercise of warrants
English 13.5 KB
2025-08-18 08:00
Regulatory News Service
Contract extension with global pharma partner
English 14.7 KB
2025-08-08 08:00
Report Publication Announcement
Investor Technical Webinar
English 13.0 KB
2025-08-07 18:24
Declaration of Voting Results & Voting Rights Announcements
Holding(s) in Company
English 52.2 KB
2025-08-05 09:05
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-07-31 14:29
Regulatory News Service
Investor Webinar
English 13.7 KB
2025-07-31 08:00
Earnings Release
Trading Update
English 21.0 KB
2025-07-28 13:25
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2025-07-24 12:48
Post-Annual General Meeting Information
Result of General Meeting
English 12.4 KB
2025-07-21 08:00
Regulatory News Service
Additional work commissioned by Unilever
English 14.6 KB

Automate Your Workflow. Get a real-time feed of all APTAMER GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for APTAMER GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA medicines for gene and cell therapies for hard-to-treat diseases.
Norway CRNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.